The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub

Brought to you by Scientific Education Support

Scientific Education Support

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

My

Create an account and access these new features:

Bookmark content to read later

Select your specific areas of interest

View aml content recommended for you

EHA 2019 | Recent advances in the field of allo-HSCT

By Emily Smith,Uwe Platzbecker

Share:

Featured:

Uwe Platzbecker

Jun 18, 2019

At the 24th Congress of the European Hematology Association (EHA), Uwe Platzbecker from the University Hospital Leipzig, Leipzig, DE, discusses the recent advances in allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML).

Prof. Plazbecker highlights two main issues with allo-HSCT. First is the risk of relapse following transplantation, and the second is the post-transplant risk of graft-versus-host disease (GvHD). Prof. Platzbecker discusses the recent advances to counteract these two issues, highlighting the use of minimal residual disease (MRD) status, measured by next generation sequencing (NGS), to assess a patient's risk of progression following allo-HSCT. He stated individual risk scores would likely be developed shortly, that are based on MRD levels and can guide treatment.

Additionally, Prof. Platzbecker explains that other ways of preventing relapse are the use of maintenance treatment and preemptive strategies. Preemptive approaches include measuring MRD rates post-transplant and treating at specified levels. The implementation of MRD in management pre- and post-transplant was described as the major current effort.

Finishing his discussion, Prof. Platzbecker talked about the treatment of GvHD, which is a threat for patients undergoing transplant. The approval of ruxolitinib, a JAK inhibitor, by the FDA for severe steroid refractory GvHD is one recent advance.

Recent advances in the field of allo-HSCT

More about...

Ruxolitinib EHA 2019 Allo-HSCT

Your opinion matters

Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?

Newsletter

Subscribe to get the best content delivered to your inbox